FDA Approves Brenzavvy (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes
January 23, 2023Jaypirca (pirtobrutinib) approved for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
January 27, 2023January 23, 2023 - The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), manufactured by the biotechnology company BeiGene, which is a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The FDA reported that the most common adverse reactions seen with zanubrutinib were a decrease in neutrophil count, upper respiratory tract infection, decrease in platelet count, hemorrhage, and musculoskeletal pain.